Trading-Stocks.de

TCR2 Therapeutics filed for an initial public offering on Friday, with plans to list on Nasdaq under the ticker symbol "TCRR". Jefferies, Leerink, BMO, Wedbush and China Renaissance are underwriters on the deal. The company said it's aiming to raise $100 million, but that number is likely a placeholder. "We are an innovative immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer," the company says in its prospectus. 

...

https://www.marketwatch.com/story/tcr2-t...-28-149113